trending Market Intelligence /marketintelligence/en/news-insights/trending/R4XlbsRX-B9Cc4YopMyRbA2 content esgSubNav
In This List

Allergan files application with US FDA for uterine fibroids treatment

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Allergan files application with US FDA for uterine fibroids treatment

The U.S. Food and Drug Administration accepted Allergan plc's new drug application for ulipristal acetate, an investigational drug to treat abnormal uterine bleeding in women with uterine fibroids.

Allergan expects the drug to be approved in the first half of 2018.

The company previously reported positive results from the second of two phase 3 clinical trials of ulipristal acetate.